Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDADOX: Transarterial Chemoembolization Using Idarubicin vs Doxorubicin in Hepatocellular Carcinoma
KCT0008166Phase 3Recruiting
- Sponsor
- Guerbet
- Start
- Apr 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of idarubicin, doxorubicin in hepatocellular carcinoma (HCC), sponsored by Guerbet. Started Apr 2023; status: recruiting.
02
Drugs
idarubicindoxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0008166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008166.